Show notes:
(1:25) Introduction to NAD
(4:09) Differences between NR, NMN, and NAD
(7:05) The discovery of NR
(12:23) Applications and commercialization of NR
(22:42) Clinical studies on the benefits of NR
(27:09) The effectiveness of NR
(29:57) Differing standards in blood marker tests
(34:05) Immune response triggered by NAD treatments
(37:53) Debunking the myths around resveratrol
(39:05) Niagen and the science behind NR supplements
(42:03) Where to find Dr. Brenner
(43:08) Outro
Who is Dr. Charles Brenner?
Charles Brenner is the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism in the Department of Diabetes & Cancer Metabolism. His laboratory focuses on disturbances in nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, in diseases and conditions of metabolic stress.
Among his most significant discoveries, he identified nicotinamide riboside as an unanticipated vitamin precursor of NAD. He also developed a quantitative metabolomic technology that allowed him to discover that the NAD system is disturbed by many diseases and conditions of metabolic stress including diabetes and cancer.
Specifically, Dr. Brenner and colleagues have found that in animal models of fatty liver, type 2 diabetes, diabetic and chemotherapeutic neuropathy, central brain injury, heart failure, postpartum and coronavirus infection, the NAD system is disturbed. In these models, provision of nicotinamide riboside is highly protective.
Dr. Brenner led the team that conducted the first clinical trial of nicotinamide riboside establishing safe oral availability and has participated in trials establishing safety and potential activities of nicotinamide riboside in clearance of liver fat and depression of common markers of inflammation. He continues to research how the NAD system is dysregulated as a function of postpartum, coronavirus infection, inflammatory conditions, diabesity and specific malignancies with the dual goals of defining mechanisms of biological regulation and developing safe preventative and therapeutic interventions for people.
Connect with Dr. Brenner:
Website: https://www.brennerlab.net/
Twitter: https://twitter.com/CharlesMBrenner
IG: https://www.instagram.com/charlesmbrenner/
Links and Resources:
Peak Performance Life
Peak Performance on Facebook
Peak Performance on Instagram
View all episodes
By Peak Performance
4.9
389389 ratings
Show notes:
(1:25) Introduction to NAD
(4:09) Differences between NR, NMN, and NAD
(7:05) The discovery of NR
(12:23) Applications and commercialization of NR
(22:42) Clinical studies on the benefits of NR
(27:09) The effectiveness of NR
(29:57) Differing standards in blood marker tests
(34:05) Immune response triggered by NAD treatments
(37:53) Debunking the myths around resveratrol
(39:05) Niagen and the science behind NR supplements
(42:03) Where to find Dr. Brenner
(43:08) Outro
Who is Dr. Charles Brenner?
Charles Brenner is the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism in the Department of Diabetes & Cancer Metabolism. His laboratory focuses on disturbances in nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, in diseases and conditions of metabolic stress.
Among his most significant discoveries, he identified nicotinamide riboside as an unanticipated vitamin precursor of NAD. He also developed a quantitative metabolomic technology that allowed him to discover that the NAD system is disturbed by many diseases and conditions of metabolic stress including diabetes and cancer.
Specifically, Dr. Brenner and colleagues have found that in animal models of fatty liver, type 2 diabetes, diabetic and chemotherapeutic neuropathy, central brain injury, heart failure, postpartum and coronavirus infection, the NAD system is disturbed. In these models, provision of nicotinamide riboside is highly protective.
Dr. Brenner led the team that conducted the first clinical trial of nicotinamide riboside establishing safe oral availability and has participated in trials establishing safety and potential activities of nicotinamide riboside in clearance of liver fat and depression of common markers of inflammation. He continues to research how the NAD system is dysregulated as a function of postpartum, coronavirus infection, inflammatory conditions, diabesity and specific malignancies with the dual goals of defining mechanisms of biological regulation and developing safe preventative and therapeutic interventions for people.
Connect with Dr. Brenner:
Website: https://www.brennerlab.net/
Twitter: https://twitter.com/CharlesMBrenner
IG: https://www.instagram.com/charlesmbrenner/
Links and Resources:
Peak Performance Life
Peak Performance on Facebook
Peak Performance on Instagram
5,013 Listeners
7,190 Listeners
7,322 Listeners
1,222 Listeners
1,080 Listeners
1,546 Listeners
715 Listeners
4,831 Listeners
3,517 Listeners
9,349 Listeners
1,200 Listeners
1,066 Listeners
734 Listeners
1,129 Listeners